期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

口服伏立康唑治疗体外循环术后肺部真菌感染14例报道 被引量：1

Voriconazole for Lung Fungal Infection:Observation and Report of Fourteen Patients after Extracorporeal Circulation Operation
原文传递
导出
摘要 目的观察伏立康唑片剂治疗体外循环术后肺部真菌感染的疗效和安全性。方法对氟康唑治疗无效的14例肺部真菌感染患者给予口服伏立康唑治疗。结果 14例患者中,治疗有效11例,总有效率78.6%,3例出现不良反应,经治疗后好转。结论口服伏立康唑是治疗体外循环术后肺部真菌感染高效、安全的药物。 OBJECTIVE To evaluate the efficacy and safety of voriconazole in the treatment of patients with lung fungal infection after extracorporeal circulation operation.METHODS Fourteen patients with lung fungal infection were given voriconazole tablet therapy after ineffective fluconazole treatment.RESULTS Eleven patients were effective,and the total effective rate was 76.5%.Adverse reaction were found and became better after relevant treatment.CONCLUSION Voriconazole is effective and safe in the treatment of patients with lung fungal infection after extracorporeal circulation operation.
作者 邹弘麟 韦杰 王萍 孙小林 赵斌 李华
机构地区 昆明市延安医院心胸外科ICU
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2010年第17期2664-2666,共3页 Chinese Journal of Nosocomiology
关键词 伏立康唑 肺部真菌感染 体外循环术后 氟康唑 Voriconazole Lung fungal infections Extracorporeal circulation operation Fluconazole
分类号 R978.1 [医药卫生—药品]
  • 相关文献

参考文献5

二级参考文献19

  • 1黄晓军.血液病/恶性肿瘤患者侵袭性真菌感染的诊断标准与治疗原则(草案)[J].中华内科杂志,2005,44(7):554-556. 被引量：423
  • 2侵袭性肺部真菌感染的诊断标准与治疗原则(草案)[J].中华内科杂志,2006,45(8):697-700. 被引量：867
  • 3Nolla-Salas J, Sitges-Serra A, Leon-Gil C, et al. Candidemia in non-neutropenic critically ill patients:analysis of prognostic factors and assessment of systemic antifungal therapy [ J ]. Intens Care Med, 1997,23:23 - 30.
  • 4Wisplinghoff H, Bischoff T, Sandra MT, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24 179 cases from a prospective nationwide surveillance study [ J ]. Clin Infect Dis, 2004,39:309 - 317.
  • 5李家泰主编.临床药理学[M].2版,北京:人民出版社,1999:678-690.
  • 6Pfaller MA, Jones RN, Doern GV, et al. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998[J].Antimicrob Agents Chemother, 2000, 44(3):747-751.
  • 7Sobel JD, Zervos M, Reed BD,et al. Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: clinical implications[J]. Antimicrob Agents Chemother, 2003,47(1): 34-38.
  • 8Safdar A, Chaturvedi V, Koll BS, et al. Prospective, multicenter surveillance study of Candida glabrata: fluconaole and itraconazole susceptibility profiles in bloodstream, invasive, and colonizing strains and differences between isolates from three urban teaching hospitals in New York City[J]. Antimicrob Agents Chemother, 2002,46(10): 3268-3272.
  • 9Holland J, Young ML, Lee O, et al. Vulvaginal carriage of yeasts other than Candida albicans[J]. Sex Transm Infect,2003,79(3):249-50.
  • 10St-Germain G, Laverdiere M, Pelletier R, et al. Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally surveillance study in Quebec,Canada[J]. J Clin Microbiol, 2001, 39(3):949-953.

共引文献927

同被引文献14

  • 1Cordonnier C,Pautas C,Maury S,et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients [J]. Bone Marrow Transplant, 2004,33 (9) : 943-948.
  • 2Catherine C, Montserrat R,Johan M,et al. Voriconazole for secondary prophylaxis of invasive fungal infections in alloge-neic stem cell transplant recipients: results of the VOSIFI study[J]. Haematologica, 2010,95 (10) : 1762-1768.
  • 3Allinson .K, Kolve H, Gumbinger HG, et al. Secondary antifungal prophylaxis in paediatric allogeneic haematopoeitic stem cell recipients[J]. J Antimicrob Chemother, 2008, 61 (3) :734-742.
  • 4Vehreschild JJ,B6hme A, Buchheidt D, et al. A double-blind trial on prophylactic voriconazole or placebo during induction chemotherapy for acute myelogenous leukaemia(AML) [J]. J Infect,2007,55(5) :445-449.
  • 5Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of as- pergillosis= clinical practice guidelines of the infectious disea- ses society of america[J]. Clin Infect Dis, 2008,46 (3) : 327- 360.
  • 6Bohme A, Ruhnke M, Buchheidt D. Infectious'Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Treatment of invasive fungal infections in cancer patients-recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) [J]. Ann Hematol, 2009,88 (2) ~ 97-110.
  • 7Thursky KA, Playford EG, Seymour JF, et al. Recommendations for the treatment of established fungal infections[J]. Intern Med J,2008,38(6b) :496-520.
  • 8Mattiuzzi GN, Mattiuzzi, Cortes J, Alvavado G,et al. Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome [J]. Support Care Cancer,2011,19 : 19-26.
  • 9Pascual A, Calandra T, Bolay S, et al. Marchetti O (2008) Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcgmes[J]. Clin Infect Dis,2008,46:201-211.
  • 10Chabrol A,Cuzin L, Huguet F,et al. Prophylaxis of invasive aspergillosis with voriconazole or caspofungin during building work in patients with acute leukemia [J]. Haematologica, 2010,95:996-1003.

引证文献1

二级引证文献1

中华医院感染学杂志
2010年 第17期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部